Cannabis and cannabinoid pills are broadly used to treat disease or alleviate symptoms, however their efficacy for specific warning signs is now not clear. To habits a systematic assessment of the benefits and adverse activities (AEs) of cannabinoids. Twenty-eight databases from inception to April 2015. Randomized scientific trials of cannabinoids for the following indications: nausea and vomiting due to chemotherapy, urge for food stimulation in HIV/AIDS, persistent pain, spasticity due to multiple sclerosis or paraplegia, depression, anxiousness disorder, sleep disorder, psychosis, glaucoma, or Tourette syndrome. Study quality was once assessed the use of the Cochrane risk of bias tool. All review stages have been carried out independently by 2 reviewers. Where possible, information were pooled the usage of random-effects meta-analysis. Patient-relevant/disease-specific outcomes, things to do of day by day living, first-class of life, international impact of change, and AEs. A whole of 79 trials (6462 participants) had been included; four had been judged at low chance of bias. Most trials showed enchancment in symptoms related with cannabinoids but these associations did no longer attain statistical value in all trials. Compared with placebo, cannabinoids were associated with a larger common number of sufferers displaying a entire nausea and vomiting response (47% vs 20%; odds ratio [OR], 3.82 [95% CI, 1.55-9.42]; three trials), discount in ache (37% vs 31%; OR, 1.41 [95% CI, 0.99-2.00]; 8 trials), a increased common discount in numerical ranking scale pain evaluation (on a 0-10-point scale; weighted imply distinction [WMD], -0.46 [95% CI, -0.80 to -0.11]; 6 trials), and average reduction in the Ashworth spasticity scale (WMD, -0.36 [95% CI, -0.69 to -0.05]; 7 trials). There was an accelerated danger of momentary AEs with cannabinoids, which includes serious AEs. Common AEs included dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucination. There was once moderate-quality proof to support the use of cannabinoids for the remedy of persistent pain and spasticity. There used to be low-quality proof suggesting that cannabinoids have been related with improvements in nausea and vomiting due to chemotherapy, weight obtain in HIV infection, sleep disorders, and Tourette syndrome. Cannabinoids were associated with an expanded hazard of temporary AEs.